ライフサイエンスコーパス: adeno-associated

1 Gene therapy with an adeno-associated vector (AAV) serotype 8 encoding the hu

2 Rats received intra-NAc administration of an adeno-associated vector that overexpressed CRF (AAV2/5-C

3 Using adeno-associated vectors (AAVs), delivery of genes encod

4 An adeno associated viral vector encoding RSPO1-Fc fusion p

5 Here we present data obtained using adeno-associated viral (AAV) constructs that drive the e

6 Adeno-associated viral (AAV) delivery of constitutively

7 ine dogs with hemophilia A were treated with adeno-associated viral (AAV) gene therapy and followed f

8 e potential utility of a novel combinatorial adeno-associated viral (AAV) gene therapy by expressing

9 ium (RPE) of Mfrp (rd6) /Mfrp (rd6) mice via adeno-associated viral (AAV) gene therapy.

10 3 weeks after adeno-associated viral (AAV) infusion, mice were exposed

11 r fused to apolipoprotein A-1 by means of an adeno-associated viral (AAV) system in the mouse model o

12 ally precise neural inactivation, we used an adeno-associated viral (AAV) vector carrying the channel

13 many nervous system targets currently is the adeno-associated viral (AAV) vector due to its desirable

14 ms were subsequently cloned into recombinant adeno-associated viral (AAV) vector genome and high-titr

15 crossed with the P23H knock-in mouse and by adeno-associated viral (AAV) vector-mediated gene augmen

16 ut of tyrosine hydroxylase was achieved with adeno-associated viral (AAV) vectors expressing Cas9 or

17 Gene complementation with adeno-associated viral (AAV) vectors is one strategy to

18 ion by systemically administered recombinant adeno-associated viral (AAV) vectors requires crossing t

19 We first engineered lentiviral (LV) and adeno-associated viral (AAV) vectors that preferentially

20 Based on these findings, we used adeno-associated viral (AAV) vectors to overexpress MIF

21 Additionally, in vivo adeno-associated viral (AAV9)-induced REEP5 depletion in

22 Recombinant adeno-associated viral (rAAV) vectors are highly promisi

23 lar gene therapy post-disease onset using an adeno-associated viral 6 (AAV6) vector carrying a functi

24 to genome editing success to date, including adeno-associated viral and lentiviral vectors for gene t

25 iarrhythmic efficacy of TASK-1 inhibition by adeno-associated viral anti-TASK-1-siRNA (small interfer

26 Anti-TASK-1 adeno-associated viral application significantly reduced

27 Adeno-associated viral delivery of the channel to both h

28 ne editing in the skin more efficiently than adeno-associated viral gene delivery.

29 ort a truncated RCas9 system compatible with adeno-associated viral packaging.

30 her excitatory or inhibitory IC neurons, and adeno-associated viral tracings to label excitatory effe

31 We used targeted adeno-associated viral vector (AAV) overexpression of hu

32 Adeno-associated viral vector (AAV)-based gene therapy i

33 LTP, we used in vivo genetic silencing by an adeno-associated viral vector (AAV2) short hairpin RNA a

34 When packaged into an adeno-associated viral vector (AAV2/9), the EKC gene was

35 Myh6, Sav1, and Tbx20, using a cardiotropic adeno-associated viral vector 9.

36 cortical neuron cultures transduced with an adeno-associated viral vector driving the GCaMP6f report

37 ety concerns after subretinal delivery of an adeno-associated viral vector encoding codon-optimized h

38 genic retinal detachment for the delivery of adeno-associated viral vector encoding Rab Escort Protei

39 We developed AAV9-GFP-AIP, an adeno-associated viral vector in which a potent CaMKII i

40 An adeno-associated viral vector was also used to reconstit

41 Adeno-associated viral vector was used to elevate the ex

42 ear of Ush1c c.216G>A mice using a synthetic adeno-associated viral vector, Anc80L65, shown to transd

43 ion and delivery of this microRNA through an adeno-associated viral vector, treated animals showed ma

44 of human clotting factors IX and X following adeno-associated viral vector-mediated intrauterine gene

45 we have explored the therapeutic efficacy of adeno-associated viral vector-mediated l-DOPA delivery t

46 Adeno-associated viral vectors (AAVs) achieve stable the

47 3 signaling axis, we used local injection of adeno-associated viral vectors (AAVs) encoding ligand-sp

48 Adeno-associated viral vectors carrying anti-TASK-1-siRN

49 We injected adeno-associated viral vectors coding for Cre-dependent

50 ek-old mdx and wild-type (C57BL10) mice with adeno-associated viral vectors encoding either MuSK or r

51 iption (up to 400-fold) when delivered using adeno-associated viral vectors in mice.

52 d gene replacement therapies using synthetic adeno-associated viral vectors to deliver the coding seq

53 Adeno-associated viral vectors to treat nervous system d

54 Adeno-associated viral vectors with different viral caps

55 ts in 34 control and 24 22qDS model mice via adeno-associated viral vectors, driven by excitatory neu

56 iver viral envelopes) and self-complementary adeno-associated viral vectors, serotype-9 (scAAV-9) in

57 We have now expanded this technology to adeno-associated viral vectors.

58 Conclusions Adeno-associated viral-based anti-TASK-1 gene therapy su

59 Adeno Associated Virus (AAV)-mediated gene expression in

60 bly of 3 types of icosahedral viral capsids: Adeno Associated Virus serotype 2 (AAV2) and Minute Viru

61 We applied STN-DBS in an adeno-associated virus (AAV) 1/2-driven human mutated A5

62 Here we report a rationally designed adeno-associated virus (AAV) 6 capsid that demonstrates

63 ession in 1-month old mdx:utr (-/-) mice via adeno-associated virus (AAV) 9-mediated RNA interference

64 Using an adeno-associated virus (AAV) approach, coupled with geno

65 the VACV CRISPR antivirals was tested using adeno-associated virus (AAV) as a packaging vector for b

66 As an alternative, we developed an adeno-associated virus (AAV) based "Provector" whose cel

67 Adeno-associated virus (AAV) capsid modification enables

68 Adeno-associated virus (AAV) capsids can deliver transfo

69 We recently developed adeno-associated virus (AAV) capsids to facilitate effic

70 ice at 6 wks were injected unilaterally with adeno-associated virus (AAV) containing either NT3 or GF

71 g RNP delivery with naturally recombinogenic adeno-associated virus (AAV) donor vectors enables site-

72 roteostasis in AMD, we delivered recombinant adeno-associated virus (AAV) encoding Abeta42 and Abeta4

73 Adeno-associated virus (AAV) exhibits anterograde transn

74 uman alpha-synuclein (alpha-syn) fibrils and adeno-associated virus (AAV) expressing human wild-type

75 ats received nodose ganglia injections of an adeno-associated virus (AAV) expressing short hairpin RN

76 PVT involvement in conflict, we injected an adeno-associated virus (AAV) expressing the genetically

77 p an effective long-term therapy for NIU, an adeno-associated virus (AAV) gene therapy approach was u

78 fective therapy for corneal vascularization, adeno-associated virus (AAV) gene therapy, exploiting a

79 al cord via intrathecal administration of an adeno-associated virus (AAV) gene transfer vector signif

80 Adeno-associated virus (AAV) has been successfully used

81 PR/Cas9 systems that can be packaged into an adeno-associated virus (AAV) hold great promise for gene

82 However, in vivo delivery of mAgrin via adeno-associated virus (AAV) into FKRP mutant mice was u

83 Adeno-associated virus (AAV) is a leading vector for vir

84 Adeno-associated virus (AAV) is a promising gene therapy

85 Adeno-associated virus (AAV) is a promising vector for g

86 Adeno-associated virus (AAV) is a replication-deficient

87 The adeno-associated virus (AAV) non-structural Rep proteins

88 ating protein (AAP) is a recently discovered adeno-associated virus (AAV) protein that promotes capsi

89 nervous system, we systemically delivered an adeno-associated virus (AAV) serotype 9 carrying the hum

90 ght to determine the efficacy of intrathymic adeno-associated virus (AAV) serotypes to transduce thym

91 The adeno-associated virus (AAV) serves as a broadly used ve

92 placement of SDS-PAGE for purity analysis of adeno-associated virus (AAV) therapeutic products of dif

93 show in adult animals successfully delivers adeno-associated virus (AAV) throughout the cervical, th

94 previously reported compassionate use of an adeno-associated virus (AAV) vector containing the human

95 The adeno-associated virus (AAV) vector effectively transduc

96 ed bilateral alBST-targeted injections of an adeno-associated virus (AAV) vector expressing short hai

97 Conventional methods to discern adeno-associated virus (AAV) vector transduction pattern

98 dministered a single intravenous dose of the adeno-associated virus (AAV) vector, AAV-BR1-CAG-NEMO, d

99 Intracerebroventricular injection of an adeno-associated virus (AAV) vector-based system encodin

100 Adeno-associated virus (AAV) vector-mediated gene delive

101 e a critical pre-clinical model for studying adeno-associated virus (AAV) vector-mediated gene therap

102 Neutralizing antibodies to adeno-associated virus (AAV) vectors are highly prevalen

103 Adeno-associated virus (AAV) vectors are preeminent in e

104 Adeno-associated virus (AAV) vectors are the leading pla

105 ants identified Anc80L65 from a set of other adeno-associated virus (AAV) vectors as a potent vector

106 that intramuscular or systemic injections of adeno-associated virus (AAV) vectors encoding nuclease-d

107 We investigated adeno-associated virus (AAV) vectors for gene delivery t

108 Gene therapy with adeno-associated virus (AAV) vectors has demonstrated ap

109 avoid these issues, and such approaches with adeno-associated virus (AAV) vectors have been shown to

110 Adeno-associated virus (AAV) vectors have been used succ

111 Adeno-associated virus (AAV) vectors have made great pro

112 Adeno-associated virus (AAV) vectors have shown promisin

113 anti-HIV monoclonal antibodies (mAbs) using adeno-associated virus (AAV) vectors holds promise for t

114 HiUGE employs adeno-associated virus (AAV) vectors of autonomous inser

115 rapeutics directly into the human body using adeno-associated virus (AAV) vectors.

116 iniaturized utrophin (uUtro), deliverable by adeno-associated virus (AAV) vectors.

117 We combined the adeno-associated virus (AAV) with the Cre-loxP site-spec

118 n mouse are systematically investigated with adeno-associated virus (AAV), an anterograde viral trace

119 ere we present two methods for radiolabeling adeno-associated virus (AAV), one of the most commonly u

120 a similar efficacy by gene augmentation via adeno-associated virus (AAV), providing a proof-of-conce

121 acrRNA)-independent CRISPR-Cpf1 systems with adeno-associated virus (AAV), we were able to build a st

122 Adeno-associated virus (AAV)-based gene therapies can re

123 Adeno-associated virus (AAV)-based gene therapy is a pro

124 lian MG proliferation, along with reports of adeno-associated virus (AAV)-based MG reprogramming and

125 HSV in a well-established mouse model, using adeno-associated virus (AAV)-delivered meganucleases, as

126 iant ribozymes enabled in vivo regulation of adeno-associated virus (AAV)-delivered transgenes, allow

127 A new adeno-associated virus (AAV)-driven somatic genome-editi

128 We found that delivery of Adeno-associated virus (AAV)-expressing miR760 in the ce

129 ficiency on atherosclerosis using a model of adeno-associated virus (AAV)-induced hypercholesterolemi

130 on as an inflammatory disease model and used adeno-associated virus (AAV)-mediated Ac45 RNA interfere

131 ine for HIV is a crucial public health need; adeno-associated virus (AAV)-mediated antibody gene deli

132 we report a genome editing approach in which adeno-associated virus (AAV)-mediated CRISPR/Cas9 delive

133 ment of a mouse model of SARS-CoV-2 based on adeno-associated virus (AAV)-mediated expression of hACE

134 We found that recombinant adeno-associated virus (AAV)-mediated expression of IL-1

135 njection of recombinant sTREM2 protein or by adeno-associated virus (AAV)-mediated expression.

136 Primary adult rat ventricular myocytes, adeno-associated virus (AAV)-mediated gene delivery in m

137 We use adeno-associated virus (AAV)-mediated gene editing to kn

138 Adeno-associated virus (AAV)-mediated gene therapy is un

139 Here, we describe the development of an adeno-associated virus (AAV)-mediated gene therapy to tr

140 To address this challenge, we first used adeno-associated virus (AAV)-mediated gene transfer to p

141 Adeno-associated virus (AAV)-mediated SaCas9-KKH deliver

142 d single guide RNA cassette are nested in an adeno-associated virus (AAV).

143 he efficient delivery of donor template with adeno-associated virus (AAV).

144 genomes derived from another parvovirus, the adeno-associated virus (AAV).

145 enic mice that receive systemic injection of adeno-associated virus (AAV)2/1-carrying truncated gRNAs

146 D1(+/L144F) MNs, and intrathecal delivery of adeno-associated virus (AAV)9-mir-17~92 improves motor d

147 To address this, we developed a novel adeno-associated virus (AAV-GLP-1R) that utilizes short

148 dy(2j)/dy(2j) mouse model of MDC1A using an adeno-associated virus (AAV9) carrying a catalytically i

149 gene was delivered to the brains of mice by adeno-associated virus (AAV9) via stereotactic injection

150 At day 28, recombinant adeno-associated virus (rAAV) (5 x 10(12) viral particle

151 Infusion of a recombinant adeno-associated virus (rAAV) containing a functional Av

152 The recent market approvals of recombinant adeno-associated virus (rAAV) gene therapies in Europe a

153 trolled release of a therapeutic recombinant adeno-associated virus (rAAV) vector overexpressing the

154 tional microdystrophin genes and recombinant adeno-associated virus (rAAV) vectors is an attractive s

155 Transplantation of PCs pretransfected with adeno-associated virus 1-vascular endothelial growth fac

156 che for either virus to replicate.IMPORTANCE Adeno-associated virus 2 (AAV2) differs from most other

157 On the other hand, adeno-associated virus 2 (AAV2) is a helper-dependent de

158 Suppression of Sema3e using adeno-associated virus 2 carrying short hairpin RNA targ

159 We have used Cas9 and adeno-associated virus 6 to correct the DeltaF508 mutati

160 ntrols, were given injections of recombinant adeno-associated virus 8 vector that expressed the prima

161 d (fl/fl) Shc mice on FFD were injected with adeno-associated virus 8-thyroxine-binding globulin-Cre-

162 Adeno-associated virus 8-vascular endothelial growth fac

163 n-human primate model of HIV infection, with adeno-associated virus 9 (AAV9)-CRISPR/Cas9 gene editing

164 /iodide symporter) to noninvasively quantify adeno-associated virus 9 (AAV9)-mediated gene expression

165 Similarly, adeno-associated virus 9 (AAV9)-mediated restoration of

166 Here, we demonstrate that a recombinant adeno-associated virus 9 (rAAV9) is highly effective for

167 Adeno-associated virus 9 -mediated cardiac overexpressio

168 ic mice were injected with M7.8L packaged in adeno-associated virus 9 at 3 days of age and 60 days of

169 phy, we performed intramuscular injection of adeno-associated virus 9 carrying the TIPE2 gene in mdx

170 1-1-93 and treated with a sCAR-Fc expressing adeno-associated virus 9 vector 1, 3, and 7 days after C

171 exclusively in cardiomyocytes by using AAV9 (adeno-associated virus 9) to deliver multiplexed single

172 Moreover, adeno-associated virus 9- RHEB restored cardiac growth t

173 ior descending coronary artery ligation, and adeno-associated virus 9-mediated in vivo overexpression

174 An adeno-associated virus 9-mediated, cardiomyocyte-specifi

175 y cardiac-specific Lrg1 delivery mediated by adeno-associated virus 9.

176 hindered by large size (limiting delivery by adeno-associated virus [AAV] vectors), off-target editin

177 l of SCLC by delivering an adenovirus (or an adeno-associated virus [AAV]) that expresses Cre recombi

178 bout 75 Snord115 genes were packaged into an adeno-associated virus and administered to a mouse model

179 D1-MSNs versus D2-MSNs using a Cre-inducible adeno-associated virus and Cre lines during cocaine cond

180 Using an adeno-associated virus approach, we validate that miR-19

181 Moreover, intra-articular injection of adeno-associated virus carrying HPIP-specific short hair

182 versely, overexpression of VZVsncRNA13 using adeno-associated virus consistently increased VZV spread

183 We present 15 adeno-associated virus constructs and 6 mouse reporter l

184 We have designed a double-stranded adeno-associated virus containing a rat proglucagon prom

185 tment of the gyrencephalic brain by systemic adeno-associated virus delivery in human neurological di

186 Intratumoral adeno-associated virus delivery of CRISPRa libraries eli

187 iabetes and two models of type 2 diabetes by adeno-associated virus delivery of renin (ReninAAV).

188 reated with a single intrathecal infusion of adeno-associated virus encoding a microRNA targeting SOD

189 BALB/c mice treated with adeno-associated virus encoding the BL6 BAG3 variant (Il

190 hydrodynamic injection or transduction with adeno-associated virus encoding the HBV genome (AAV-HBV)

191 Next, the anterograde transport of an adeno-associated virus expressing DREADDs was paired wit

192 of stress-susceptible or mice injected with adeno-associated virus expressing shRNA against Cldn5 ca

193 es; disruption of anchoring in vivo using an adeno-associated virus gene therapy vector inhibited car

194 Additionally, adeno-associated virus has demonstrated outstanding pote

195 We injected Cre-dependent adeno-associated virus in an Rbp4-Cre transgenic mouse l

196 rformed by orotracheal transgene delivery of adeno-associated virus in mouse models of PH.

197 In addition, introduction of 3xMyc-FXR1 via adeno-associated virus into mice leads to the redistribu

198 of CRISPRa, we injected CRISPRa-recombinant adeno-associated virus into the hypothalamus, which led

199 e injection of an engineered virus, often an adeno-associated virus or herpes simplex virus, among ma

200 s9 mRNA, compared with cells transduced with adeno-associated virus or lentivirus expressing SaCas9.

201 Delivery of apoptotic RASER by adeno-associated virus selectively ablated ErbB-hyperact

202 gets by performing intraspinal injections of adeno-associated virus serotype 2 (AAV2)-BDNF vector.

203 elation to recent clinical translation in an adeno-associated virus serotype 2-mediated human aromati

204 Adeno-associated virus serotype 5 (AAV5) is being develo

205 single intravenous dose of a codon-optimized adeno-associated virus serotype 5 (AAV5) vector encoding

206 Finally, adeno-associated virus serotype 8 (AAV8)-mediated reexpr

207 es and human leukocyte antigen (HLA)-A2.1 by adeno-associated virus serotype 9 (AAV9) vectors.

208 We modulated expression of FTO by using adeno-associated virus serotype 9 (in vivo), adenovirus

209 23a was expressed using a self-complementary adeno-associated virus serotype 9 (scAAV9) viral vector

210 Adeno-associated virus serotype 9 carrying cardiac-speci

211 In contrast, mice injected with adeno-associated virus serotype 9 encoding PDE4B (10(12)

212 Similarly, adeno-associated virus serotype 9 encoding PDE4B slowed

213 cyte-specific overexpression of PDE4B and an adeno-associated virus serotype 9 encoding PDE4B.

214 An in vivo rescue experiment with adeno-associated virus serotype 9 TnT-MEK1-CA nearly abo

215 CRISPR/Cas9-based cardiac gene editing using adeno-associated virus serotype 9 to deliver a single sh

216 In vivo, AAV9 (adeno-associated virus serotype 9)-mediated cardiac over

217 ic implications, we found that prior in vivo Adeno-associated virus serotype 9-mediated gene delivery

218 METHODS AND Using an in vivo Adeno-associated virus serotype 9-mediated gene transfer

219 ons, we employed systemic administration via adeno-associated virus serotype 9.

220 Pak2 activation by genetic overexpression or adeno-associated virus serotype-9-based gene delivery wa

221 Moreover, IRE-1 activator, Quercetin, and adeno-associated virus serotype-9-delivered XBP-1s were

222 Cbeta was genetically targeted using a novel adeno-associated virus shuttle vector to deliver microRN

223 ticular administration of miR-204-expressing adeno-associated virus significantly decelerates OA prog

224 g within the VTA, we delivered Cre-inducible adeno-associated virus that drives the expression of flu

225 er a single intravenous administration of an adeno-associated virus that encodes CRISPR (AAV-CRISPR).

226 ice (NTS-HIF-1alpha(-/-) ) by microinjecting adeno-associated virus that expressed Cre-recombinase in

227 injected into NAc variants of a new designer adeno-associated virus that permits robust retrograde ac

228 from a transgene or after infection with an adeno-associated virus that transferred an overlength HB

229 in mice, using Cre recombinase delivered by adeno-associated virus to knockout endogenous hepatic In

230 Vectors based on adeno-associated virus type 2 (AAV2) are powerful tools

231 of HCC in patients with hepatitis B virus or adeno-associated virus type 2 infection might involve ac

232 patients infected with hepatitis B virus or adeno-associated virus type 2, due to integration of the

233 fferent transgenic Cre mice or injected with adeno-associated virus type 8 (AAV8) Cre and fed diets t

234 cus aureus) and guide RNA constructs into an adeno-associated virus vector and systemically delivered

235 SG -( K(b) D(b)) (null) ( IA(null)) mice via adeno-associated virus vector increased human CD45(+) ce

236 Genomic integration of the adeno-associated virus vector into Cas9 target sites cau

237 F21 by administration of an FGF21-expressing adeno-associated virus vector recapitulated these compli

238 Intravascular injection of certain adeno-associated virus vector serotypes can cross the bl

239 erapy approach for Alzheimer's disease using adeno-associated virus vector-based knockdown of CD33 re

240 receptor retargeting.IMPORTANCE Recombinant adeno-associated virus vectors (rAAVs), based on AAV8 an

241 Using retrograde adeno-associated virus vectors and transgenic mice expre

242 Intrahippocampal injections of adeno-associated virus vectors containing the astrocyte-

243 atory elements in the context of recombinant adeno-associated virus vectors has enabled cell-type-res

244 gnaling in a common mouse model of AD, using adeno-associated virus vectors normalized glutamate sign

245 human patients, and gene augmentation using adeno-associated virus vectors robustly sustained the re

246 assemblies, similar to the best recombinant adeno-associated virus vectors.

247 nd loss of KLF5 function approaches and AAV (adeno-associated virus)-mediated Klf5 delivery in mice s

248 wild-type mice via stereotaxic injection of adeno-associated virus, we found that adult cerebellar n

249 For HBV, HPV16, HPV18 and adeno-associated virus-2 (AAV2), viral integration was a

250 was also increased in CPVT mice, and further adeno-associated virus-9-induced overexpression of SN at

251 e (RyR2 [ryanodine receptor 2]-R2474S) using adeno-associated virus-9-induced overexpression.

252 e treatment of a mouse model of OPMD with an adeno-associated virus-based gene therapy combining comp

253 Adeno-associated virus-based transduction of Dnase1l3 in

254 d deep sequencing results confirmed that our adeno-associated virus-CRISPR/Cas9 strategy was very eff

255 by a single-dose systemic administration of adeno-associated virus-delivered CRISPR-Cas9 components

256 Here, we show that adeno-associated virus-driven expression of progranulin

257 noted similar results in mice infected with adeno-associated virus-expressing small hairpin RNAs tar

258 gulation and that induction of NRF2 using an adeno-associated virus-mediated approach in hepatocytes

259 of spared axons, using projection-specific, adeno-associated virus-mediated chemogenetic neuronal si

260 imary striatal cell culture model of HD, and adeno-associated virus-mediated Elk-1 overexpression all

261 Furthermore, adeno-associated virus-mediated expression of CCN1 rever

262 ene deletion in the NAc in adult mice, using adeno-associated virus-mediated expression of cre recomb

263 tem, we intravitreally delivered recombinant adeno-associated virus-mediated expression of soluble Fm

264 To assess efficacy in vivo, we used adeno-associated virus-mediated expression of the most p

265 Conditional gene deletion and adeno-associated virus-mediated gene delivery in the mou

266 sue of the JCI, Wang et al. demonstrate that adeno-associated virus-mediated overexpression of TGF-be

267 Adeno-associated virus-mediated targeting of RGMa to mou

268 In contrast, transgenic or adeno-associated virus-mediated TNFAIP3 gene delivery in

269 The adeno-associated virus-progranulin vector only transduce

270 R induced by intraparenchymal delivery of an adeno-associated virus-short hairpin RNA construct was s

271 1 was overexpressed by use of a cardiotropic adeno-associated virus.

272 y of CRISPR/Cas9 gene editing machinery with adeno-associated virus.

273 he murine heart was performed by means of an adeno-associated virus.

274 We generated multifunctional hybrid adeno-associated virus/phage (AAVP) particles to enable

275 replication, we constructed two recombinant adeno-associated-virus 2 (rAAV2) vectors encoding CIP fu

276 Adeno-associated viruses (AAV) are composed of nonenvelo

277 Adeno-associated viruses (AAV) are helper-dependent parv

278 ockout (L-G6pc(-/-) ) mice were treated with adeno-associated viruses (AAVs) 2 or 8 directed against

279 Adeno-associated viruses (AAVs) are dependoparvoviruses

280 Adeno-associated viruses (AAVs) are frequently used for

281 Among viral delivery systems, adeno-associated viruses (AAVs) are relatively safe and

282 Adeno-associated viruses (AAVs) are typically single-str

283 es of CRISPR-associated protein 9 (Cas9) and adeno-associated viruses (AAVs) evades adaptive immune r

284 Adeno-associated viruses (AAVs) from clade E are often u

285 in defined cell types, recombinase-dependent adeno-associated viruses (AAVs) have become the tool of

286 fficient AAV genome transcription.IMPORTANCE Adeno-associated viruses (AAVs) have proven to be effect

287 rity and tight junction integrity.IMPORTANCE Adeno-associated viruses (AAVs) have recently emerged at

288 Delivery via adeno-associated viruses (AAVs) is limited by AAV packag

289 sting neutralizing antibodies (NAbs) against adeno-associated viruses (AAVs) pose a major, unresolved

290 ified here by stamping cultured neurons with adeno-associated viruses (AAVs), is completed in a few m

291 Recombinant adeno-associated viruses (rAAVs) are currently considere

292 Recombinant adeno-associated viruses (rAAVs) are efficient gene deli

293 ved by transducing the BSCs with recombinant adeno-associated viruses (rAAVs) that express alpha-synu

294 o synaptic damage in vivo, we have generated adeno-associated viruses AAV-Tat and AAV-Exo-Tat viruses

295 eta receptor 2 [sTGFbetaR2]) delivered using adeno-associated viruses and explored their ability to m

296 B19 is a long-known human pathogen, whereas adeno-associated viruses are nonpathogenic.

297 We treated mice with either adeno-associated viruses encoding a control (green fluor

298 Local injection of adeno-associated viruses expressing sgRNA-guided CjABE i

299 of tauopathy utilizing neonatal delivery of adeno-associated viruses expressing wild-type (WT) or mu

300 oteinaceous nanocontainers and genome-packed adeno-associated viruses.